论文部分内容阅读
目的:探讨希罗达同期放、化疗对中晚期鼻咽癌患者治疗的安全性和有效性。方法:将2006年1月～2007年10月就诊我院的50例初诊局部晚期(Ⅲ、Ⅳ期)鼻咽癌病人随机分为IMRT组和IMRT+希罗达组。化疗方法为希罗达750～1 000 mg/m2,每天2次口服(第1～14天),3周为1个疗程,共2个疗程。放射治疗于第1程化疗的第1天开始,给予调强根治性放疗。结果:IMRT+希罗达组完全缓解(CR)23例,CR率为92%,IM-RT CR20例,CR率80%。IMRT+希罗达组病人8例(32%)IMRT组4例(16%)出现Ⅲ度口腔粘膜炎,IMRT+希罗达组病人5例(20%)IMRT组2例(8%)出现Ⅲ度放射性皮炎,无治疗相关死亡。结论:初步结果显示希罗达同步放疗,治疗中晚期鼻咽癌病人是一个安全、方便、耐受良好且疗效高的治疗方法,值得临床推广应用。
Objective: To investigate the safety and efficacy of Xeloda in the treatment of patients with advanced nasopharyngeal carcinoma during the same period of radiotherapy and chemotherapy. Methods: From January 2006 to October 2007, 50 cases of newly diagnosed locally advanced stage Ⅲ and Ⅳ nasopharyngeal carcinoma patients in our hospital were randomly divided into IMRT group and IMRT + Xeloda group. Chemotherapy for Xeloda 750 ~ 1 000 mg / m2, 2 times a day orally (days 1 to 14), 3 weeks for a course of treatment, a total of 2 courses. Radiation therapy in the first course of chemotherapy started on the first day, given tonifying radical radiotherapy. Results: In the IMRT + Xeloda group, 23 cases were completely relieved (CR) with CR rate of 92% and IM-RT CR of 20 cases with CR rate of 80%. Grade III oral mucositis occurred in 8 patients (16%) in IMRT + Xeloda group and in 2 patients (8%) in IMRT + Xeloda group (3%) Radiation dermatitis, no treatment-related deaths. Conclusion: The preliminary results show that Xeloda synchrotron radiation is a safe, convenient, well-tolerated and effective therapeutic method for the treatment of advanced nasopharyngeal carcinoma patients, which is worthy of clinical application.